After the activity, the most commonly used treatment regimens were dual therapy with metformin and an injectable GLP-1 RA (12/50, 24%) or triple therapy with metformin, an injectable GLP-1 RA, and a sodium-glucose cotransporter-2 inhibitor (SGLT2i; 20%, 10/50; Figure 7, where the bar graph shows the number of patients who received specific diabetes treatment regimens). The gene discussed is SLC5A2; the disease is diabetes mellitus.